Daily Stock Analysis, ARRY, Array Biopharma Inc, priceseries

Array Biopharma Inc. Daily Stock Analysis
Stock Information
Open
11.20
Close
11.37
High
11.43
Low
11.07
Previous Close
11.18
Daily Price Gain
0.19
YTD High
13.40
YTD High Date
Feb 10, 2017
YTD Low
8.50
YTD Low Date
Jan 3, 2017
YTD Price Change
2.81
YTD Gain
32.83%
52 Week High
13.40
52 Week High Date
Feb 10, 2017
52 Week Low
2.44
52 Week Low Date
Feb 24, 2016
52 Week Price Change
8.66
52 Week Gain
319.56%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 20. 2015
4.60
Feb 24. 2015
7.87
24 Trading Days
71.13%
Link
LONG
Mar 1. 2016
2.68
Mar 9. 2016
2.88
6 Trading Days
7.59%
Link
LONG
Apr 12. 2016
3.02
Apr 26. 2016
3.20
10 Trading Days
5.96%
Link
LONG
May 24. 2016
3.28
Jun 7. 2016
3.63
9 Trading Days
10.82%
Link
LONG
Jun 28. 2016
3.43
Jul 14. 2016
3.66
11 Trading Days
6.75%
Link
LONG
Nov 7. 2016
6.03
Dec 13. 2016
8.47
25 Trading Days
40.53%
Link
LONG
Jan 12. 2017
10.11
Jan 30. 2017
10.65
11 Trading Days
5.31%
Link
Company Information
Stock Symbol
ARRY
Exchange
NasdaqGM
Company URL
http://www.arraybiopharma.com
Company Phone
3033816600
CEO
Ron Squarer
Headquarters
Colorado
Business Address
3200 WALNUT STREET, BOULDER, CO 80301
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001100412
About

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.

Description

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib and Encorafenib for the treatment of cancer. Its drug candidates in Phase II clinical trials include Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASC08/Danoprevir, a protease inhibitor for Hepatitis C virus; ASLAN001/ARRY-543, a pan-HER inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; and LY2606368, a chk-1 inhibitor for cancer. The company's Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer; and ONT-380/ARRY-380, a HER2 inhibitor for breast cancer, as well as Phase I drug candidate includes GDC-0994, an ERK inhibitor for cancer and LOXO-101, a PanTrk inhibitor for cancer. Array BioPharma Inc. has collaboration agreements with Biogen Idec MA Inc.; Array and Celgene Corporation and Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc.; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc, as well as a collaboration with Dana-Farber Cancer Institute. The company was founded in 1998 and is headquartered in Boulder, Colorado.